Oramed Pharmaceuticals Inc.

NasdaqCM:ORMP Stock Report

Market Cap: US$158.5m

Oramed Pharmaceuticals Management

Management criteria checks 3/4

Oramed Pharmaceuticals' CEO is Nadav Kidron, appointed in Mar 2006, has a tenure of 20.17 years. total yearly compensation is $4.77M, comprised of 13% salary and 87% bonuses, including company stock and options. directly owns 6.91% of the company’s shares, worth $10.95M. The average tenure of the management team and the board of directors is 13.4 years and 8 years respectively.

Key information

Nadav Kidron

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage12.98%
CEO tenure20.2yrs
CEO ownership6.9%
Management average tenure13.4yrs
Board average tenure8yrs

Recent management updates

Recent updates

Seeking Alpha • Dec 24

Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback

Summary Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group. Validating the Protein Oral Delivery Platform in this subset could unlock broader applications beyond insulin. Read the full article on Seeking Alpha
Analysis Article • Nov 21

Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential

Investors appear disappointed with Oramed Pharmaceuticals Inc.'s ( NASDAQ:ORMP ) recent earnings, despite the decent...
Analysis Article • Nov 13

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • May 31

We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Aug 24

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • May 03

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Dec 22

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Sep 21

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Summary Results from Oramed Pharmaceuticals's first phase 3 study ORA-D-013-1, using ORMD-0801 for the treatment of patients with Type 2 Diabetes, is expected January 2023. Results from the ongoing Cohorts A and B, using Oravax for Covid-19, are going to be read out Q3 and Q4 of 2022 respectively. An oral GLP-1 drug is being developed in the pipeline to treat patients with Type 2 Diabetes. The global Type 2 Diabetes market opportunity could double to $58.7 billion by 2025. Oramed Pharmaceuticals (ORMP) is a great speculative biotech play to look into. The reason why I state that is because it is developing an oral insulin drug, known as ORMD-0801 for the treatment of patients with Type 2 Diabetes. The reason why I think it can provide traders/investors an opportunity is because it is gearing up to report results from its phase 3 study using this drug for this patient population in January of 2023. This will be results from a late-stage study known as ORA-D-013-1. It did present preliminary results from the use of ORMD-0801 for the treatment of patients with non-alcoholic steatohepatitis ((NASH)) about a week ago. However, the primary endpoint was just looking at safety. The secondary endpoint of liver fat reduction at 12 weeks was not revealed. Just that there was a positive trend in favor of ORMD-0801. It remains to be seen if this NASH indication can be moved forward, but regardless the entire future of this biotech hinges on the phase 3 study using ORMD-0801 for the treatment of patients with Type 2 Diabetes. Even then, it does have a backup clinical candidate in the pipeline known as ORMD-0901 which is an oral GLP-1 analog. There are many other biotechs though who are targeting GLP-1, so whether or not this drug eventually shatters the competition remains to be seen. Still, it is nice to see that this biotech it at least working on another drug to target Type 2 diabetes. There is a final opportunity in developing an oral virus like particle ((VLP)) Covid-19 vaccine known as Oravax. Data is supposed to be out in Q3 of 2022 and then again Q4 of 2022. While not guaranteed for success, it is nice to see another shot on goal in the pipeline. However, the broader strategy here is to apply oral vaccine technology towards other indications that would typically require a vaccine. If somewhat successful with Covid-19, then it's possible to explore such other vaccine indications. Oral Insulin For Type 2 Diabetes Might Become A Reality The first program to go over involves the use of ORMD-0801 for the treatment of patients with Type 2 Diabetes. Type 2 Diabetes occurs as when the body is unable to use insulin properly to control sugar in the bloodstream. This is a larger market opportunity for sure. The reason why I state that is because T2D occurs in 95% of people with diabetes. Some symptoms of Type 2 Diabetes are: Blurry vision Fatigue Extreme thirst Frequent urination As I noted before, this is a very large market opportunity. It is expected that the global market opportunity could double to $58.7 billion by 2025. This is a very good opportunity for Oramed Pharma. In order for Oramed to eventually obtain FDA approval for ORMD-0801 for the treatment of patients with T2D, it has to succeed in one or both of the two ongoing phase 3 studies it has. The first phase 3 study which is currently ongoing is known as ORA-D-013-1. The goal for this trial was to enroll at least 675 patients, but happy to say that they were able to go over targeted enrollment to 710 patients. The primary endpoint of this study is improvement of glycemic control as assessed by A1c over a 26 week period. The secondary endpoint of this late-stage study is a change from baseline in fasting plasma glucose at 26 weeks. As far as a catalyst goes for this program, it is expected that topline results from the phase 3 ORA-D-013-1 study using ORMD-0801 for the treatment of patients with T2D, will be released by January of 2023. First and foremost, the biotech must meet the primary endpoint to succeed for this particular study. Of course, it may also have to do well in the 2nd phase 3 trial I will talk about below. However, should the drug do well in both studies and receive FDA approval, then it will have a few competitive advantages. One competitive advantage being that the drug is given orally instead of as an injection which is a huge improvement to quality of life. It just makes sense, patients would much rather take a drug orally instead of being injected. Secondly, the fact that it is given orally may give an advantage in terms of efficacy. That's because the drug starts to work even before reaching the patient's bloodstream. Lastly, the use of ORMD-0801 for T2D may have an advantage in terms of safety risks. Injectable insulin currently available on the market may cause weight gain and hypoglycemia (lower blood sugar range away from normal). Hopefully Oramed Pharma is successful, because it holds the potential to have the first FDA approved oral insulin drug. It would be huge, because the company already sees that an oral insulin drug would do well from a survey that was done. Such an IQVIA market survey showed that about 76% of physicians would likely prescribe oral insulin instead of injections. In order to really assess whether or not ORMD-0801 is capable of helping patients with T2D, it has an ongoing second phase 3 study in which it is advancing, known as ORA-D-013-2. This trial is expected to enroll up to a total of 450 Type 2 Diabetes patients. These are patients who don't receive an adequate glycemic control by diet only or diet and metformin monotherapy. This late-stage study is a double-blind trial that intends to randomize patients 1:1 into two specific cohorts: One cohort of patients receiving 8 mg ORMD-0801 at night Another cohort of patients receiving once placebo drug at night The primary endpoint here is no different than the primary endpoint for the first phase 3 ORA-D-013-1 study noted above. That is, the efficacy of ORMD-0801 will be compared to placebo in terms of improving glycemic control as assessed by A1c over a 26 week treatment period. The secondary endpoint will be the comparing of ORMD-0801 to placebo in maintaining glycemic control over a 52-week treatment period. I will state that this program could be a bit of a wait. The main topline data in January of 2023 will be crucial of course to see if ORMD-0801 is successful in treating patients with T2D. The problem is that this second phase 3 study will take a big longer. Looking at clinicaltrials site the estimated primary completion date for it is not until at least April of 2023. This means that data from this particular study may not be available until the 2nd half of 2023. Additional Shots On Goal As I indicated above, Oramed is also exploring the use of oral drug ORMD-0801 for the treatment of patients with NASH. Oramed did report preliminary results from the phase 2 study. However, I believe that its future with respect to this indication remains to be seen. The reason why I state that is because of course the safety was reported to be good, the problem is that there was no mention of what the actual percentage of liver fat reduction was. Measurements such as MRI PDFF(%) by MRI, steatosis and fibrosis measured by FibroScan, lipids and HbA1c all showed clinically meaningful trends in favor of ORMD-0801. To be fair, the secondary endpoint was made to assess efficacy in reducing liver fat content in patients with NASH and T2D in a non-statistically significant manner. I believe there is more proof of concept to be done here, therefore, if it does advance forward it would be a great bonus for the pipeline. I would have liked to at least seen some numbers over the 12-week period. While Oramed does have the two ongoing phase 3 studies using ORMD-0801 for the treatment of patients with Type 2 Diabetes, it is not leaving this drug as the only chance of moving a candidate forward for this indication. Having said that, it is pushing forward with a GLP-1 analog for Type 2 Diabetes. There, however, are two specific issues to be aware of though. The first issue being that this drug, known as ORMD-0901, is only being tested in a phase 1 for starters. Secondly, there are a host of competitors who are also developing their very own oral GLP-1 drug. I just wrote an article on Pfizer (PFE) discussing that the big pharma is gearing towards presenting data for its own oral small molecule GLP-1 drug for diabetes. The main premise is that it intends to hold an analyst and investor webcast presentation of oral GLP-1 data at the European Association for the Study of Diabetes (EASD) 2022. This data is going to presented on Wednesday, September 21, 2022 at 4:30 p.m. EDT. There are many other companies with GLP-1 agonists who currently have a portion of the market. Such companies are Novo Nordisk (NVO), Eli Lilly (LLY), AstraZeneca (AZN) and Sanofi (SNY).
Seeking Alpha • Sep 09

Oramed to hand Korean rights for insulin capsule

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a company focused on treatments for diabetes, announced a non-binding agreement with Medicox Co., Ltd. granting the latter exclusive right and license to seek regulatory nod and distribute ORMP’s oral insulin capsule ORMD-0801 in South Korea. The non-binding memorandum of agreement is only for discussion purposes and forms the basis for a definitive distribution license agreement, ORMP said in a regulatory filing Thursday. The 10-year deal includes a transfer price per capsule, milestone, and royalty payments. ORMP has also received a $2M non-refundable payment from Medicox in connection with an undertaking not to grant distribution and license rights to ORMD-0801 in the Republic of Korea until Dec. 15, 2022. The company expects an early 2023 topline data readout for ORMD-0801 from an ongoing Phase 3 trial in type 2 diabetes ahead of a potential submission of a marketing application to the FDA in 2024.
Seeking Alpha • Jul 07

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Oramed Pharmaceuticals (NASDAQ:ORMP), a clinical-stage pharma focused on diabetes and liver diseases, announced on Thursday that despite the challenges in enrollment, the company plans to share data from its Phase 1 trial for oral COVID-19 shot Oravax in 3Q 2022. Issuing a letter to shareholders, Oramed (ORMP) Chief Executive Nadav Kidron noted that the company introduced an additional clinical site amid slower than anticipated enrollment. Oramed (ORMP) has completed the enrollment and dosing in Cohort A with no safety issues so far. While topline data for Cohort A are expected in 3Q, plans are underway to achieve the enrollment target for the Cohort B within this quarter, with data anticipated in 4Q 2022. Recording $169M in cash and Investments as of March 31, Oramed (ORMP) said its cash runway would be adequate to complete the pivotal Phase 3 trials for ORMD-0801 towards a potential FDA approval of the oral insulin candidate. In December, Oramed (ORMP) announced that its subsidiary, Oravax Medical signed an agreement with a Vietnam-based company to sell its oral COVID-19 vaccine in Southeast Asia.
Analysis Article • Jun 12

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Apr 14

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity. This is a $15bn market, and there is very little competition.
Analysis Article • Feb 23

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Dec 23

Oramed And The Hurdles Of Developing Oral Insulin

Oramed is a leading developer of an oral formulation of human insulin. It uses a permeability enhancer to enable intestinal absorption. A recent cash raise caused the stock to fall drastically.
Analysis Article • Nov 02

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 04

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Giant pharma Merck's co-developed oral coronavirus drug with Ridgeback Biotherapeutics has raised interest in non-injected vaccine alternatives. The space was already occupied by Oramed, a clinical-stage biotech, whose oral vaccine is based on its POD technique, together with India's Premas Biotech COVID technology. This is a huge market, but also a highly competitive one due to the sheer number of biotechs involved, but the Israeli company can use previous experience in diabetes and NASH. Still, the fact that its shares have been adversely impacted after Merck's update shows that investors suffered from acidity when digesting the news. I remain bullish on this diversified stock, with market action also showing that its shares have been less battered than for established COVID biotechs.
Analysis Article • Aug 24

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

We have been pretty impressed with the performance at Oramed Pharmaceuticals Inc. ( NASDAQ:ORMP ) recently and CEO...
Analysis Article • Jul 21

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, Oramed...

CEO Compensation Analysis

How has Nadav Kidron's remuneration changed compared to Oramed Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$5mUS$620k

US$63m

Sep 30 2025n/an/a

US$44m

Jun 30 2025n/an/a

-US$24m

Mar 31 2025n/an/a

-US$28m

Dec 31 2024US$2mUS$540k

-US$19m

Sep 30 2024n/an/a

US$4m

Jun 30 2024n/an/a

US$21m

Mar 31 2024n/an/a

US$10m

Dec 31 2023US$2mUS$463k

US$6m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$20m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$7mUS$491k

-US$37m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$46m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021n/an/a

-US$35m

Nov 30 2021n/an/a

-US$25m

Aug 31 2021US$4mUS$466k

-US$22m

May 31 2021n/an/a

-US$18m

Feb 28 2021n/an/a

-US$15m

Dec 31 2020n/an/a

-US$22m

Nov 30 2020n/an/a

-US$15m

Aug 31 2020US$2mUS$439k

-US$12m

May 31 2020n/an/a

-US$11m

Feb 29 2020n/an/a

-US$13m

Nov 30 2019n/an/a

-US$13m

Aug 31 2019US$2mUS$419k

-US$14m

Compensation vs Market: Nadav's total compensation ($USD4.77M) is above average for companies of similar size in the US market ($USD1.59M).

Compensation vs Earnings: Nadav's compensation has been consistent with company performance over the past year.

CEO

Nadav Kidron (51 yo)

20.2yrs
Tenure
US$4,774,660
Compensation

Mr. Nadav Kidron, Esq., is Director of Lifeward Ltd. from March 25, 2026. Mr. Kidron has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Tec...

Leadership Team

NamePositionTenureCompensationOwnership
Nadav Kidron
President20.2yrsUS$4.77m6.91%
$ 11.0m
Joshua Hexter
Chief Operating & Business Officer6.7yrsUS$1.88m1.96%
$ 3.1m
Miriam Kidron
Chief Scientific Officer & Director20.2yrsUS$2.17m1.82%
$ 2.9m
Avraham Gabay
CFO, Treasurer & Secretary1.9yrsUS$753.15k0.73%
$ 1.2m
13.4yrs
Average Tenure
53yo
Average Age

Experienced Management: ORMP's management team is seasoned and experienced (13.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nadav Kidron
President20.2yrsUS$4.77m6.91%
$ 11.0m
Miriam Kidron
Chief Scientific Officer & Director20.2yrsUS$2.17m1.82%
$ 2.9m
Jay Skyler
Member of Scientific Advisory Board6.3yrsno datano data
Eleuterio Ferrannini
Member of Scientific Advisory Board19.3yrsno datano data
Harold Jacob
Member of Scientific Advisory Board9.5yrsUS$20.00kno data
Avram Hershko
Member of Scientific Advisory Board17.8yrsno datano data
G. Alexander Fleming
Member of Scientific Advisory Board6.4yrsno datano data
Roy Eldor
Member of the Scientific Advisory Board9.8yrsno datano data
Anne Peters
Member of Scientific Advisory Board3.9yrsno datano data
Arie Mayer
Independent Director6.4yrsUS$218.96k0.18%
$ 285.3k
Julio Rosenstock
Member of Scientific Advisory Board6.3yrsno datano data
Benjamin Shapiro
Independent Director3yrsUS$199.97k4.83%
$ 7.7m
8.0yrs
Average Tenure
71yo
Average Age

Experienced Board: ORMP's board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 21:22
End of Day Share Price 2026/05/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oramed Pharmaceuticals Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Edward NashCanaccord Genuity
Robert LeBoyerLadenburg Thalmann & Company